Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22


CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.

Andersch L, Radke J, Klaus A, Schwiebert S, Winkler A, Schumann E, Grunewald L, Zirngibl F, Flemmig C, Jensen MC, Rossig C, Joussen A, Henssen A, Eggert A, Schulte JH, Künkele A.

BMC Cancer. 2019 Sep 9;19(1):895. doi: 10.1186/s12885-019-6131-1.


Reflection of neuroblastoma intratumor heterogeneity in the new OHC-NB1 disease model.

Thole TM, Toedling J, Sprüssel A, Pfeil S, Savelyeva L, Capper D, Messerschmidt C, Beule D, Groeneveld-Krentz S, Eckert C, Gambara G, Henssen AG, Finkler S, Schulte JH, Sieber A, Bluethgen N, Regenbrecht CRA, Künkele A, Lodrini M, Eggert A, Deubzer HE.

Int J Cancer. 2019 Jul 15. doi: 10.1002/ijc.32572. [Epub ahead of print]


Transmission of chromosomally integrated human herpes virus-6A via haploidentical stem cell transplantation poses a risk for virus reactivation and associated complications.

Oevermann L, Zimmermann C, Voigt S, Künkele A, Lobitz S, Eggert A, Schulte JH, Kaufer BB, Deubzer HE.

Bone Marrow Transplant. 2019 Apr 15. doi: 10.1038/s41409-019-0530-4. [Epub ahead of print] No abstract available.


Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.

Han Y, Lindner S, Bei Y, Garcia HD, Timme N, Althoff K, Odersky A, Schramm A, Lissat A, Künkele A, Deubzer HE, Eggert A, Schulte JH, Henssen AG.

Cancer Lett. 2019 Mar 31;445:24-33. doi: 10.1016/j.canlet.2018.12.012. Epub 2019 Jan 4.


Manufacture of Chimeric Antigen Receptor T Cells from Mobilized Cyropreserved Peripheral Blood Stem Cell Units Depends on Monocyte Depletion.

Künkele A, Brown C, Beebe A, Mgebroff S, Johnson AJ, Taraseviciute A, Rolczynski LS, Chang CA, Finney OC, Park JR, Jensen MC.

Biol Blood Marrow Transplant. 2019 Feb;25(2):223-232. doi: 10.1016/j.bbmt.2018.10.004. Epub 2018 Oct 10.


Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.

Arnhold V, Schmelz K, Proba J, Winkler A, Wünschel J, Toedling J, Deubzer HE, Künkele A, Eggert A, Schulte JH, Hundsdoerfer P.

Oncotarget. 2017 Dec 18;9(2):2304-2319. doi: 10.18632/oncotarget.23409. eCollection 2018 Jan 5.


RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.

Gottlieb A, Althoff K, Grunewald L, Thor T, Odersky A, Schulte M, Deubzer HE, Heukamp L, Eggert A, Schramm A, Schulte JH, Künkele A.

Oncotarget. 2017 Apr 25;8(17):27882-27891. doi: 10.18632/oncotarget.15840.


The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.

Pajtler KW, Sadowski N, Ackermann S, Althoff K, Schönbeck K, Batzke K, Schäfers S, Odersky A, Heukamp L, Astrahantseff K, Künkele A, Deubzer HE, Schramm A, Sprüssel A, Thor T, Lindner S, Eggert A, Fischer M, Schulte JH.

Oncotarget. 2017 Jan 24;8(4):6730-6741. doi: 10.18632/oncotarget.14268.


MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.

Fabian J, Opitz D, Althoff K, Lodrini M, Hero B, Volland R, Beckers A, de Preter K, Decock A, Patil N, Abba M, Kopp-Schneider A, Astrahantseff K, Wünschel J, Pfeil S, Ercu M, Künkele A, Hu J, Thole T, Schweizer L, Mechtersheimer G, Carter D, Cheung BB, Popanda O, von Deimling A, Koster J, Versteeg R, Schwab M, Marshall GM, Speleman F, Erb U, Zoeller M, Allgayer H, Simon T, Fischer M, Kulozik AE, Eggert A, Witt O, Schulte JH, Deubzer HE.

Oncotarget. 2016 Oct 11;7(41):66344-66359. doi: 10.18632/oncotarget.11662.


Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility.

Künkele A, Taraseviciute A, Finn LS, Johnson AJ, Berger C, Finney O, Chang CA, Rolczynski LS, Brown C, Mgebroff S, Berger M, Park JR, Jensen MC.

Clin Cancer Res. 2017 Jan 15;23(2):466-477. doi: 10.1158/1078-0432.CCR-16-0354. Epub 2016 Jul 7.


Neoadjuvant/adjuvant treatment of high-risk retinoblastoma: a report from the German Retinoblastoma Referral Centre.

Künkele A, Wilm J, Holdt M, Lohmann D, Bornfeld N, Eggert A, Temming P, Schulte JH.

Br J Ophthalmol. 2015 Jul;99(7):949-53. doi: 10.1136/bjophthalmol-2014-306222. Epub 2015 Jan 12.


Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD.

Künkele A, Johnson AJ, Rolczynski LS, Chang CA, Hoglund V, Kelly-Spratt KS, Jensen MC.

Cancer Immunol Res. 2015 Apr;3(4):368-79. doi: 10.1158/2326-6066.CIR-14-0200. Epub 2015 Jan 9.


MiR-34a deficiency accelerates medulloblastoma formation in vivo.

Thor T, Künkele A, Pajtler KW, Wefers AK, Stephan H, Mestdagh P, Heukamp L, Hartmann W, Vandesompele J, Sadowski N, Becker L, Garrett L, Hölter SM, Horsch M, Calzada-Wack J, Klein-Rodewald T, Racz I, Zimmer A, Beckers J, Neff F, Klopstock T, De Antonellis P, Zollo M, Wurst W, Fuchs H, Gailus-Durner V, Schüller U, de Angelis MH, Eggert A, Schramm A, Schulte JH.

Int J Cancer. 2015 May 15;136(10):2293-303. doi: 10.1002/ijc.29294. Epub 2014 Nov 25.


The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.

Pajtler KW, Weingarten C, Thor T, Künkele A, Heukamp LC, Büttner R, Suzuki T, Miyata N, Grotzer M, Rieb A, Sprüssel A, Eggert A, Schramm A, Schulte JH.

Acta Neuropathol Commun. 2013 May 29;1:19. doi: 10.1186/2051-5960-1-19.


The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.

Künkele A, Grosse-Lordemann A, Schramm A, Eggert A, Schulte JH, Bachmann HS.

BMC Cancer. 2013 Oct 2;13:452. doi: 10.1186/1471-2407-13-452.


Long-term follow-up of pediatric patients receiving total body irradiation before hematopoietic stem cell transplantation and post-transplant survival of >2 years.

Künkele A, Engelhard M, Hauffa BP, Mellies U, Müntjes C, Hüer C, Eggert A, Schulte JH, Kremens B.

Pediatr Blood Cancer. 2013 Nov;60(11):1792-7. doi: 10.1002/pbc.24702. Epub 2013 Jul 24.


Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre.

Künkele A, Jurklies C, Wieland R, Lohmann D, Bornfeld N, Eggert A, Schulte JH.

Br J Ophthalmol. 2013 Oct;97(10):1277-83. doi: 10.1136/bjophthalmol-2013-303452. Epub 2013 Jul 17.


Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.

Heukamp LC, Thor T, Schramm A, De Preter K, Kumps C, De Wilde B, Odersky A, Peifer M, Lindner S, Spruessel A, Pattyn F, Mestdagh P, Menten B, Kuhfittig-Kulle S, Künkele A, König K, Meder L, Chatterjee S, Ullrich RT, Schulte S, Vandesompele J, Speleman F, Büttner R, Eggert A, Schulte JH.

Sci Transl Med. 2012 Jul 4;4(141):141ra91. doi: 10.1126/scitranslmed.3003967.


Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.

Künkele A, De Preter K, Heukamp L, Thor T, Pajtler KW, Hartmann W, Mittelbronn M, Grotzer MA, Deubzer HE, Speleman F, Schramm A, Eggert A, Schulte JH.

Neuro Oncol. 2012 Jul;14(7):859-69. doi: 10.1093/neuonc/nos115. Epub 2012 May 16.


MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.

Schulte JH, Lindner S, Bohrer A, Maurer J, De Preter K, Lefever S, Heukamp L, Schulte S, Molenaar J, Versteeg R, Thor T, Künkele A, Vandesompele J, Speleman F, Schorle H, Eggert A, Schramm A.

Oncogene. 2013 Feb 21;32(8):1059-65. doi: 10.1038/onc.2012.106. Epub 2012 Apr 9.


Myoglobin plasma level related to muscle mass and fiber composition: a clinical marker of muscle wasting?

Weber MA, Kinscherf R, Krakowski-Roosen H, Aulmann M, Renk H, Künkele A, Edler L, Kauczor HU, Hildebrandt W.

J Mol Med (Berl). 2007 Aug;85(8):887-96. Epub 2007 Jun 30.


Relationship of skeletal muscle perfusion measured by contrast-enhanced ultrasonography to histologic microvascular density.

Weber MA, Krakowski-Roosen H, Delorme S, Renk H, Krix M, Millies J, Kinscherf R, Künkele A, Kauczor HU, Hildebrandt W.

J Ultrasound Med. 2006 May;25(5):583-91.


Supplemental Content

Loading ...
Support Center